Navigation Links
Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on Plaintiffs’ Request to Unseal Key Clinical Studies Data
Date:12/14/2013

(PRWEB) December 14, 2013

Risperdal plaintiffs have asked a Pennsylvania judge to unseal clinical studies data, citing its importance to the public interest, according to court documents. The Rottenstein Law Group LLP, which represents clients in Risperdal lawsuits, notes that the documents detail potential risks associated with the antipsychotic drug.

The request from attorneys representing plaintiffs in about 300 Pennsylvania state Risperdal lawsuits is a response to an initial request from Johnson & Johnson and subsidiary Janssen Pharmaceuticals to uphold a 2011 order to keep the documents sealed, according to court documents (In re: Risperdal Litigation; Case No. 100300296, Philadelphia Court of Common Pleas, Pennsylvania.)

J&J previously argued that because the documents are generated for researchers and regulators, and not for the general public, there is no reason to unseal them, according to court documents.

“The plaintiffs in these cases allege that Risperdal causes gynecomastia, which is the enlargement of breast tissue in males,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “They believe the sealed data speaks to their allegations, and so they are requesting that the courts order the documents to be made available.”

Recently, J&J agreed to pay $2.2 billion in civil and criminal fines to settle claims it improperly marketed the antipsychotic medication Risperdal to children, seniors and people with developmental disabilities, according to a Nov. 4 New York Times story.* The United States Department of Justice announced the settlement, which also includes heart-failure drug Natrecor and the antipsychotic Invega. The federal government alleges that J&J marketed the drug to high-risk groups from 1999 to 2005, the story said. Part of the settlement includes J&J’s pleading guilty to a criminal misdemeanor for its role in promotion of the drug to those groups.

Risperdal has been shown to almost double the risk of heart disease and pneumonia in elderly dementia patients, according to the U.S. Food and Drug Administration.**

The Rottenstein Law Group LLP encourages those who believe they or their loved ones have suffered from the alleged side effects of Risperdal to visit the firm's website to learn about Risperdal lawsuits and side effects.

*nytimes.com/2013/11/05/business/johnson-johnson-to-settle-risperdal-improper-marketing-case.html

**http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm152291.htm

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
plus.google.com/106070664376281033016

Read the full story at http://www.prweb.com/releases/risperdal-lawsuits/gynecomastia/prweb11421722.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Parker Waichman LLP Commends Arkansas Attorney General for Backing Fine Against Johnson & Johnson over Risperdal Off-Label Marketing Allegations
2. The Consumer Justice Foundation Launches RisperdalLaw.com, an Informational Web Site Dealing with Alleged Risperdal Side Effects Including Gynecomastia
3. Bernstein Liebhard LLP Investigating Risperdal Lawsuits on Behalf of Victims of Male Breast Growth Allegedly Caused by Risperdal
4. New Risperdal Lawsuit Filed in Pennsylvania Litigation; Alleges Male Breast Growth Injuries Caused by Anti-Psychotic Medication, Bernstein Liebhard LLP Reports
5. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Settlement in Risperdal Marketing Investigation
6. Risperdal Lawsuits: $2.2 Billion Settlement Between Federal Government, Johnson & Johnson Over Alleged Illegal Marketing of Risperdal, Other Medications
7. Risperdal Lawsuit News: Johnson & Johnson To Pay Over $2.2 Billion In Risperdal and Invega Settlement Draws Comment From Wright & Schulte LLC
8. J&J to Pay $2.2B to Settle Allegations Over Its Marketing of Risperdal; Parker Waichman LLP Applauds Efforts of Whistleblowers in Helping Compel Resolution
9. Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on $2 Billion Risperdal Settlement Report
10. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Mounting Claims Involving Risperdal Gynecomastia Allegations in Pennsylvania Litigation
11. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Release of Emails from Johnson & Johnson’s Janssen Subsidiary in Federal Risperdal Settlement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... Source ... botanicals and 100 percent pure essential oils, announced the company had a successful visit ... , The annual ECRM event gives companies that work in the nutritional, sports and ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out of Australia ... attended the January ECRM trade show in Hilton Head, SC. , International Protein ... to create a line of products that would elevate her fitness regime. At this ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a ... has set out for each of his children. “The Angel” is the creation of ... Music in New York City, and impassioned writer. , When asked of her new ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Journey to Christmas:” a beautiful and enchanting tale ... published author, Kimberly Cordoves, a mother of three in Oklahoma City, and a devoted woman ... of writing a book has been in the back of my mind for years, but ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Management System: an On-demand E-learning system for Clinical and Regulatory education for ... is based on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... LEXINGTON, Massachusetts , January 19, 2017 ... SHPG ) announced that the U.S. Food and Drug ... resubmission of a New Drug Application (NDA) for SHP465, ... being evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity ... decision on or around June 20, 2017, the designated ...
(Date:1/19/2017)... BEACH, Florida , January 19, 2017 /PRNewswire/ ... incoming Trump administration appears serious about reducing the ... advancements and innovation in the medical drug industry, ... forge ahead with new clinical trials and development ... Pharma companies forging ahead with recent developments include:  ...
(Date:1/19/2017)... -- The Global Therapy Partnering Terms and Agreements since ... and agreements entered into by the world,s leading healthcare ... deals by value - Deals listed by company A-Z, ... report provides understanding and access to the partnering deals ... companies. The report provides an analysis of partnering ...
Breaking Medicine Technology: